Literature DB >> 9024715

Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.

M A Silberman1, A W Partin, R W Veltri, J I Epstein.   

Abstract

BACKGROUND: Prior studies have suggested that tumor angiogenesis (microvessel density [MVD]) may be of prognostic significance in patients with prostate carcinoma.
METHODS: The authors examined the relationship of MVD in intermediate grade prostate carcinomas with stage at radical prostatectomy (RP) and progression after RP. For the former group, 109 RP specimens with Gleason sums of 6 and 7 were studied: 34 organ-confined tumors, 37 with capsular penetration, 21 with seminal vesicle involvement, and 17 with pelvic lymph node metastasis. For the latter group, 87 RP specimens were studied that had a Gleason sum of 5 to 7 for which the patients underwent follow-up of at least 7 years or until progression. Thirty-seven patients (43%) progressed at a mean of 3.5 years (range, 1-8 years). Representative sections of each tumor were stained for CD31 and "hot spot" microvessels were quantitated in a 3.14-mm2 area.
RESULTS: In the first arm, there was no relationship between MVD and stage at RP. In the second arm, the mean MVD in tumors that progressed was significantly higher than in nonprogressors (43.0 +/- 26.1 vs. 29.0 +/- 13.1; P < 0.0001 by Wilcoxon-Gehan statistic). MVD and Gleason sum were independent statistically significant predictors of progression (MVD, P < 0.0001; Gleason sum, P < 0.0001 by Cox proportional hazards model).
CONCLUSIONS: MVD is an independent significant predictor of progression after RP for tumors with a Gleason sum of 5 to 7. Because these comprise the majority of RP specimens, it is this group for which discrimination of biologic potential is most needed. Angiogenesis may be useful in the prognostic stratification of patients beyond that possible using stage and grade alone.

Entities:  

Mesh:

Year:  1997        PMID: 9024715     DOI: 10.1002/(sici)1097-0142(19970215)79:4<772::aid-cncr14>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.

Authors:  Philip P Fitchev; Susan M Wcislak; Chung Lee; Anders Bergh; Charles B Brendler; Veronica M Stellmach; Susan E Crawford; Constantine D Mavroudis; Mona L Cornwell; Jennifer A Doll
Journal:  Lab Invest       Date:  2010-05-10       Impact factor: 5.662

2.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.

Authors:  A M De Marzo; V L Marchi; J I Epstein; W G Nelson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

Review 4.  Contrast specific imaging in the detection and localization of prostate cancer.

Authors:  Hessel Wijkstra; Margot H Wink; Jean J M C H de la Rosette
Journal:  World J Urol       Date:  2004-10-05       Impact factor: 4.226

5.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

6.  Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer.

Authors:  Lutz Trojan; Daniel Thomas; Thomas Knoll; Rainer Grobholz; Peter Alken; Maurice Stephan Michel
Journal:  Urol Res       Date:  2004-05

7.  A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.

Authors:  Srikala S Sridhar; Anthony M Joshua; Richard Gregg; Christopher M Booth; Nevin Murray; Jovana Golubovic; Lisa Wang; Pamela Harris; Kim N Chi
Journal:  Clin Genitourin Cancer       Date:  2014-06-08       Impact factor: 2.872

Review 8.  Molecular and genetic prognostic factors of prostate cancer.

Authors:  Arnab Chakravarti; Gary Guotang Zhai
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

9.  Prognostic value of microvessel density in prostate cancer: a tissue microarray study.

Authors:  Andreas Erbersdobler; Hendrik Isbarn; Kira Dix; Isabel Steiner; Thorsten Schlomm; Martina Mirlacher; Guido Sauter; Alexander Haese
Journal:  World J Urol       Date:  2009-08-28       Impact factor: 4.226

10.  Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.

Authors:  Robert W Veltri; Sumit Isharwal; M Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin
Journal:  Prostate       Date:  2008-12-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.